Literature DB >> 15870922

Diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody (rituximab): a case with severe liver dysfunction due to liver cirrhosis and hepatocellular carcinoma.

Seiji Nakai1, Tsutomu Masaki, Takamichi Shintani, Akihiro Deguchi, Yasuhiko Kimura, Takashi Himoto, Kazutaka Kurokohchi, Seishiro Watanabe, Shigeki Kuriyama.   

Abstract

Primary gastric lymphoma is relatively rare in the scope of gastric malignancies. Here we report a case of diffuse large B-cell primary gastric lymphoma treated successfully with the CD20 monoclonal antibody, rituximab, alone. Because the patient had a complication of severe liver dysfunction due to hepatitis C virus induced-liver cirrhosis and hepatocellular carcinoma, it was difficult to treat the primary gastric lymphoma using standard therapy such as surgical resection and cocktail chemotherapy. Therefore, rituximab was administered to the patient, resulting in complete remission of the primary gastric lymphoma. This case indicates that monotherapy using only rituximab may be a promising option for the treatment of patients with diffuse large B-cell lymphoma accompanied by severe liver dysfunction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15870922

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

1.  Efficient palliative involved-field radiotherapy on highly progressive diffuse large B-cell primary gastric lymphoma with liver cirrhosis.

Authors:  Junji Kohisa; Kenya Kamimura; Akito Iwanaga; Kazuhiko Shioji; Hirokazu Kawai; Takeshi Suda; Kenji Suzuki; Junko Sakurada; Makoto Naito; Yutaka Aoyagi
Journal:  Clin J Gastroenterol       Date:  2012-03-11

Review 2.  Practical guidelines for dose individualization of anticancer targeted drugs.

Authors:  María Isabel Sáez; Cristina Quero; José Manuel Trigo; Begoña Muros; Emilio Alba
Journal:  Clin Transl Oncol       Date:  2012-10-12       Impact factor: 3.405

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.